These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 27405225

  • 1. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
    Ziemssen T, Gass A, Wuerfel J, Bayas A, Tackenberg B, Limmroth V, Linker R, Mäurer M, Haas J, Stangel M, Meergans M, Harlin O, Hartung HP.
    BMC Neurol; 2016 Jul 12; 16():98. PubMed ID: 27405225
    [Abstract] [Full Text] [Related]

  • 2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul 12; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 3. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
    Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O, Raab P, Lukas C, Chan A, Stangel M, Gold R.
    J Neurol Neurosurg Psychiatry; 2014 Oct 12; 85(10):1177-8. PubMed ID: 24700881
    [No Abstract] [Full Text] [Related]

  • 4. Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.
    Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L.
    Eur J Neurol; 2023 Oct 12; 30(10):3357-3361. PubMed ID: 37485841
    [Abstract] [Full Text] [Related]

  • 5. Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients.
    Cordioli C, De Rossi N, Rasia S, Lodoli G, Capra R.
    Neurol Sci; 2015 Mar 12; 36(3):489-91. PubMed ID: 25109815
    [No Abstract] [Full Text] [Related]

  • 6. Biomarkers identification for PML monitoring, during Natalizumab (Tysabri®) treatment in Relapsing-Remitting Multiple Sclerosis.
    Lanza Cariccio V, Bramanti P, Mazzon E.
    Mult Scler Relat Disord; 2018 Feb 12; 20():93-99. PubMed ID: 29353737
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O.
    Expert Rev Neurother; 2016 May 12; 16(5):471-81. PubMed ID: 27008031
    [Abstract] [Full Text] [Related]

  • 8. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 12; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 9. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis.
    Kapica-Topczewska K, Collin F, Tarasiuk J, Czarnowska A, Chorąży M, Mirończuk A, Kochanowicz J, Kułakowska A.
    Eur Neurol; 2020 Apr 12; 83(5):487-492. PubMed ID: 33027785
    [Abstract] [Full Text] [Related]

  • 10. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X.
    Rev Neurol; 2015 Feb 16; 60(4):164-8. PubMed ID: 25670046
    [Abstract] [Full Text] [Related]

  • 11. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
    Zhang Y, Wright C, Flores A.
    J Med Case Rep; 2018 Jul 01; 12(1):187. PubMed ID: 29960601
    [Abstract] [Full Text] [Related]

  • 12. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar 01; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 13. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 01; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis.
    Rodríguez de Castro B, Barbosa CM, Ayastuy Ruiz A, Fernández González B.
    Eur J Hosp Pharm; 2021 Mar 01; 28(2):112-114. PubMed ID: 33608441
    [Abstract] [Full Text] [Related]

  • 15. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Mar 01; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 16. Spanish consensus on the use of natalizumab (Tysabri®)-2013.
    Fernández O, García-Merino JA, Arroyo R, Álvarez-Cermeño JC, Izquierdo G, Saiz A, Olascoaga J, Rodríguez-Antigüedad A, Prieto JM, Oreja-Guevara C, Hernández MA, Moral E, Meca J, Montalbán X.
    Neurologia; 2015 Jun 01; 30(5):302-14. PubMed ID: 24360652
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Jun 01; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 18. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S, Rollot F, Casey R, Pique J, Marignier R, Mathey G, Edan G, Brassat D, Ruet A, De Sèze J, Maillart E, Zéphir H, Labauge P, Derache N, Lebrun-Frenay C, Moreau T, Wiertlewski S, Berger E, Moisset X, Rico-Lamy A, Stankoff B, Bensa C, Thouvenot E, Heinzlef O, Al-Khedr A, Bourre B, Vaillant M, Cabre P, Montcuquet A, Wahab A, Camdessanché JP, Tourbah A, Guennoc AM, Hankiewicz K, Patry I, Nifle C, Maubeuge N, Labeyrie C, Vermersch P, Laplaud DA, OFSEP Investigators.
    JAMA Neurol; 2020 Jan 01; 77(1):94-102. PubMed ID: 31479149
    [Abstract] [Full Text] [Related]

  • 19. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug 01; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

  • 20. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K, Gold R.
    J Neurol; 2011 Nov 01; 258(11):1920-8. PubMed ID: 21647730
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.